- Home
- PZZA vs MNKD Comparison
PZZA vs MNKD Comparison
Compare PZZA & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZZA
- MNKD
- Stock Information
- Founded
- PZZA 1984
- MNKD 1991
- Country
- PZZA United States
- MNKD United States
- Employees
- PZZA N/A
- MNKD N/A
- Industry
- PZZA Restaurants
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- PZZA Consumer Discretionary
- MNKD Health Care
- Exchange
- PZZA Nasdaq
- MNKD Nasdaq
- Market Cap
- PZZA 1.5B
- MNKD 1.6B
- IPO Year
- PZZA 1993
- MNKD 2004
- Fundamental
- Price
- PZZA $47.99
- MNKD $4.98
- Analyst Decision
- PZZA Buy
- MNKD Buy
- Analyst Count
- PZZA 13
- MNKD 6
- Target Price
- PZZA $56.18
- MNKD $8.92
- AVG Volume (30 Days)
- PZZA 2.1M
- MNKD 2.2M
- Earning Date
- PZZA 02-27-2025
- MNKD 02-26-2025
- Dividend Yield
- PZZA 3.83%
- MNKD N/A
- EPS Growth
- PZZA 2.42
- MNKD N/A
- EPS
- PZZA 2.54
- MNKD 0.10
- Revenue
- PZZA $2,059,387,000.00
- MNKD $285,504,000.00
- Revenue This Year
- PZZA $3.33
- MNKD $19.46
- Revenue Next Year
- PZZA $4.09
- MNKD $14.44
- P/E Ratio
- PZZA $18.89
- MNKD $49.80
- Revenue Growth
- PZZA N/A
- MNKD 43.50
- 52 Week Low
- PZZA $35.28
- MNKD $3.97
- 52 Week High
- PZZA $72.88
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- PZZA 57.41
- MNKD 29.84
- Support Level
- PZZA $43.53
- MNKD $5.01
- Resistance Level
- PZZA $46.81
- MNKD $5.74
- Average True Range (ATR)
- PZZA 2.55
- MNKD 0.23
- MACD
- PZZA -0.24
- MNKD -0.04
- Stochastic Oscillator
- PZZA 53.48
- MNKD 9.74
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.